Sarepta Therapeutics, Inc.
LSE: 0L35.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Douglas S. Ingram
- Employees
- 1,372
- Headquarters
- Cambridge, United States
- IPO year
- 2018
- Market cap
- $2.1B
- Website
- https://www.sarepta.com
Loading 0L35…
Loading profile data…Frequently asked questions about 0L35
What does Sarepta Therapeutics, Inc. (0L35.L) do?
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
Where does 0L35.L trade?
Sarepta Therapeutics, Inc. (0L35.L) trades on the London Stock Exchange.
What sector is 0L35.L in?
Sarepta Therapeutics, Inc. (0L35.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Sarepta Therapeutics, Inc.?
Douglas S. Ingram is the chief executive officer of Sarepta Therapeutics, Inc. (0L35.L).
Where is Sarepta Therapeutics, Inc. headquartered?
Sarepta Therapeutics, Inc. is headquartered in United States.
Does 0L35.L pay a dividend?
Sarepta Therapeutics, Inc. (0L35.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0L35.L go public?
Sarepta Therapeutics, Inc. (0L35.L) completed its initial public offering in 2018.